News
EFPIA hails joint action on counterfeit drugs
The pan-European medicines verification system uses an anti-tampering device together with 2D barcoding to verify the authenticity of medicinal products and is currently being implemented with all supply chain stakeholders in Europe. It is being introduced...
News
Washington University-developed new breast cancer vaccine shows promise
Researchers at Washington University School of Medicine in St. Louis, US, have reported preliminary data from a small clinical trial of a new breast cancer vaccine. Led by Washington University breast cancer surgeon and senior...
News
Japan’s Otsuka to acquire Avanir for $3.5bn
Japan-based Otsuka Pharmaceutical has signed an agreement to acquire US-based Avanir Pharmaceuticals for $3.5bn. Otsuka, through its wholly-owned subsidiary Otsuka America, will acquire Avanir for $17 per share in cash. Otsuka will launch a...
News
Daiichi and UCB Biopharma partner to introduce epilepsy treatment Lacosamide in Japan
Japan-based Daiichi Sankyo has signed an agreement with UCB Biopharma to jointly commercialise Lacosamide for the treatment of patients with epilepsy in Japan. As part of the deal, UCB will manufacture and supply the product...
News
AstraZeneca and Cancer Research UK collaborate for new cancer medicines screening
British-Swedish drugmaker AstraZeneca has signed a memorandum of understanding (MoU) to provide drug discovery facilities for Cancer Research UK at its new MRC UK Centre for Lead Discovery in Cambridge. As part of...
News
Hilleman signs MoU with Bangladesh firms to develop oral cholera vaccine
Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine. The collaboration was established to fast track...
News
Servier to market Intarcia’s type 2 diabetes treatment outside US and Japan
France-based pharmaceutical research company Servier has partnered with Intarcia Therapeutics to develop and commercialise its ITCA 650, outside the US and Japan. ITCA 650 is Intarcia's investigational therapy for the treatment of type 2 diabetes. The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















